A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Nicholas Foreman, MD
Study ID
Protocol Number: 19-2270
More information available at ClinicalTrials.gov: NCT03962543
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers